Fertility-sparing Neoadjuvant Chemotherapy in >4cm Cervical Cancer with Dr. David Viveros-Carreño
In this episode of the IJGC podcast, Editor-in-Ch…
BMJ talk medicine · BMJ Group
June 13, 202229m 22s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. David Viveros-Carreño. Dr. Viveros-Carreño is a Gynecologic Oncologist at Instituto Nacional de Cancerología, Clínica Universitaria Colombia and Clínica Los Nogales in Bogotá, Colombia.
Highlights:
- Fertility-sparing surgery after neoadjuvant chemotherapy in cervical cancer >4 cm is feasible, but the evidence is limited and should be considered as an experimental intervention.
- A complete pathological response occurred in 56% of patients.
- At least one pregnancy was achieved in 67% of cases and 60% were pre-term deliveries.